108 related articles for article (PubMed ID: 34174446)
1. Non-cytomembrane PD-L1: An atypical target for cancer.
Ying H; Zhang X; Duan Y; Lao M; Xu J; Yang H; Liang T; Bai X
Pharmacol Res; 2021 Aug; 170():105741. PubMed ID: 34174446
[TBL] [Abstract][Full Text] [Related]
2. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
Lu MM; Yang Y
Front Immunol; 2024; 15():1395332. PubMed ID: 38726017
[TBL] [Abstract][Full Text] [Related]
3. The implication of the PD-1/PD-L1 checkpoint in chronic periodontitis suggests novel therapeutic opportunities with natural products.
Bailly C
Jpn Dent Sci Rev; 2020 Nov; 56(1):90-96. PubMed ID: 32612718
[TBL] [Abstract][Full Text] [Related]
4. Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist.
Ng KW; Attig J; Young GR; Ottina E; Papamichos SI; Kotsianidis I; Kassiotis G
Elife; 2019 Nov; 8():. PubMed ID: 31729316
[TBL] [Abstract][Full Text] [Related]
5. Treating cancer through modulating exosomal protein loading and function: The prospects of natural products and traditional Chinese medicine.
Meng L; Zhang C; Yu P
Pharmacol Res; 2024 May; 203():107179. PubMed ID: 38615876
[TBL] [Abstract][Full Text] [Related]
6. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
Zhang X; Huang X; Xu J; Li E; Lao M; Tang T; Zhang G; Guo C; Zhang X; Chen W; Yadav DK; Bai X; Liang T
Nat Commun; 2021 Jul; 12(1):4536. PubMed ID: 34315872
[TBL] [Abstract][Full Text] [Related]
7. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases.
Bailly C; Thuru X; Quesnel B
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34204509
[TBL] [Abstract][Full Text] [Related]
8. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Li E; Huang X; Zhang G; Liang T
J Exp Clin Cancer Res; 2021 Sep; 40(1):279. PubMed ID: 34479614
[TBL] [Abstract][Full Text] [Related]
9. Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity.
Meng F; Yu Z; Zhang D; Chen S; Guan H; Zhou R; Wu Q; Zhang Q; Liu S; Venkat Ramani MK; Yang B; Ba XQ; Zhang J; Huang J; Bai X; Qin J; Feng XH; Ouyang S; Zhang YJ; Liang T; Xu P
Mol Cell; 2021 Oct; 81(20):4147-4164.e7. PubMed ID: 34453890
[TBL] [Abstract][Full Text] [Related]
10. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
Sheng J; Zhang J; Wang L; Tano V; Tang J; Wang X; Wu J; Song J; Zhao Y; Rong J; Cheng F; Wang J; Shen Y; Wen L; He J; Zhang H; Li T; Zhang Q; Bai X; Lu Z; Liang T
Gut; 2022 Jun; 71(6):1176-1191. PubMed ID: 34253573
[TBL] [Abstract][Full Text] [Related]
11. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.
Niu M; Liu Y; Yi M; Jiao D; Wu K
Front Immunol; 2022; 13():827921. PubMed ID: 35386715
[TBL] [Abstract][Full Text] [Related]
12. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
13. Glucose Metabolism: The Metabolic Signature of Tumor Associated Macrophage.
Zhang Q; Wang J; Yadav DK; Bai X; Liang T
Front Immunol; 2021; 12():702580. PubMed ID: 34267763
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer.
Sholl LM
Mod Pathol; 2022 Jan; 35(Suppl 1):66-74. PubMed ID: 34608245
[TBL] [Abstract][Full Text] [Related]
15. Gallbladder Adenosquamous Cancer with Situs Inversus Totalis: A Case Report and Literature Review.
Huang J; Yang H; Wang M; Zhao X; Shao S; Zhang F; Que R; Hu Q; Liang T
Onco Targets Ther; 2021; 14():4299-4304. PubMed ID: 34349522
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Evaluation of 8-(
Wu X; Li H; Liu H; Ding X; Chen X; Yin C; Gao Y; Ma J
ACS Med Chem Lett; 2024 Apr; 15(4):518-523. PubMed ID: 38628793
[TBL] [Abstract][Full Text] [Related]
17. Tumour cell-expressed PD-L1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signalling in liver cancer.
Zhao M; Yuan H; Yang G; Wang Y; Bu Y; Zhang H; Zhao L; Lv P; Yun H; Geng Y; Feng J; Hou C; Wang S; Zhang N; Lu W; Zhang X
JHEP Rep; 2024 Apr; 6(4):101009. PubMed ID: 38455469
[TBL] [Abstract][Full Text] [Related]
18. Subcellular localization of PD-L1 and cell-cycle-dependent expression of nuclear PD-L1 variants: implications for head and neck cancer cell functions and therapeutic efficacy.
Schulz D; Feulner L; Santos Rubenich D; Heimer S; Rohrmüller S; Reinders Y; Falchetti M; Wetzel M; Braganhol E; Lummertz da Rocha E; Schäfer N; Stöckl S; Brockhoff G; Wege AK; Fritsch J; Pohl F; Reichert TE; Ettl T; Bauer RJ
Mol Oncol; 2024 Feb; 18(2):431-452. PubMed ID: 38103190
[TBL] [Abstract][Full Text] [Related]
19. Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy.
Wang Y; Zhou Y; Yang L; Lei L; He B; Cao J; Gao H
Adv Sci (Weinh); 2024 Jan; 11(1):e2303175. PubMed ID: 37934012
[TBL] [Abstract][Full Text] [Related]
20. PD-L1's Role in Preventing Alloreactive T Cell Responses Following Hematopoietic and Organ Transplant.
Handelsman S; Overbey J; Chen K; Lee J; Haj D; Li Y
Cells; 2023 Jun; 12(12):. PubMed ID: 37371079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
